NCT04050462 2025-10-16
Nivolumab Combined With BMS-986253 in HCC Patients
NYU Langone Health
Phase 2 Terminated
Clinical Trials
12 trialsNCT03697564 2025-08-06
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
University of California, San Diego
Phase 2 Completed
NCT04331067 2025-04-23
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT03336216 2024-07-23
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT03502330 2024-07-03
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Yale University
Phase 1 Completed
NCT03927105 2024-03-18
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03431948 2023-02-16
C4-MOSART
University of Chicago
Phase 1 Completed
NCT03335540 2022-09-26
ADVISE
Bristol-Myers Squibb
Phase 1 Completed
NCT02526017 2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1 Completed
NCT03599362 2021-10-19
Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
NYU Langone Health
Phase 2 Terminated
NCT02471716 2021-08-31
FPA008-002
Five Prime Therapeutics, Inc.
Phase 1/2 Completed
NCT03158272 2020-12-21
A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread
Bristol-Myers Squibb
Phase 1 Completed